Clinical trials: Graves Orbitopathy
Graves' Ophthalmopathy
Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.
- Trial name
- NCT03922321
- Testing
- RVT-1401
- Where
- 4 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Immunovant Sciences GmbH
Graves' Ophthalmopathy (GO)
ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )
The purpose of the current study is to assess the efficacy and safety/tolerability of three dose regimens of RVT-1401 in the treatment of active, moderate to severe GO participants.
- Trial name
- NCT03938545
- Testing
- RVT-1401 (Administered via subcutaneous injection)
- Where
- 25 sites in United States, Canada and 3 more
- Volunteers
- 65 people
- Sponsor
- Immunovant Sciences GmbH